Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
4 trials since 2013, 0 ongoing, by the sponsor of the products; see every authorized trial
An open label study to evaluate the long-term safety and efficacy of odevixibat (A4250) in patients with alagille…Aug 26, 2021 · Closed · Odevixibat (A4250)
A phase 3 double-blind, randomized, placebo-controlled study of the safety and efficacy of odevixibat (A4250) in…Dec 22, 2020 · Closed · Odevixibat (A4250)
An open-label extension study to evaluate long-term efficacy and safety of A4250 in children with progressive familial…Sep 7, 2018 · Closed · Odevixibat (A4250)
A double-blind, randomized, placebo-controlled, phase 3 study to demonstrate efficacy and safety of A4250 in children…Mar 21, 2018 · Closed · A4250
Payments to doctors (Open Payments)
What this company reported paying US doctors and teaching hospitals each year, $7.3M of it for research; see every company
$2.1M20222022Paid$2.1M
$2.3M20232023Paid$2.3Mvs 2022+$243K
$2.3M20242024Paid$2.3Mvs 2023−$6K
$1.7M20252025Paid$1.7Mvs 2024−$569K
Orphan designations (FDA)
One designation since 1983, 0 approved for the designated use, matched by the sponsor's name; see all orphan designations
3-([3…Treatment of Primary Sclerosing Cholangitis · Nov 15, 2022
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.